US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Charlotte’s Web Founder Aims For FDA Approval Of Autism Spectrum Disorder Drug
Joel Stanley, the founder and former CEO of Charlotte’s Web, is leading an effort to achieve approval from the FDA for a novel treatment to treat autism spectrum ...
oncnursingnews2d
FDA Approves Treosulfan With Fludarabine for alloHSCT Conditioning in AML and MDS
Treosulfan plus fludarabine was approved by the FDA for children and adults with AML or MDS before allogenic hematopoietic ...
Cure Today2d
FDA Approves GRAFAPEX/Fludarabine Before alloHSCT in AML and MDS
The FDA has approved GRAFAPEX™ and fludarabine as a preparative regimen in acute myeloid leukemia or myelodysplastic syndrome ...
Targeted Oncology2d
FDA Greenlights Treosulfan/Fludarabine Combo for AlloHSCT in AML and MDS
The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation ...
ALS News Today2d
Zydus cleared to begin US trial of oral therapy usnoflast for ALS
Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.
Cancer Therapy Advisor3d
Grafapex Approved as Part of Conditioning Regimen for HSCT in AML, MDS
The FDA has approved Grafapex (treosulfan) for use in combination with fludarabine as a preparative regimen for allogeneic HSCT in patients aged 1 year and older with AML or MDS.
Medscape3d
FDA Approves Grafapex (Treosulfan) for HSCT Conditioning
After a delayed approval, treosulfan’s manufacturer is hopeful the alkylating agent will become the new gold standard in the United States.
verywellhealth3d
Why It's Hard for Patients to Get the Newest Alzheimer's Drugs
Access to the new Alzheimer's drugs is limited by strict eligibility criteria, long wait times, and a lack of infusion ...
Monthly Prescribing Reference3d
Grafapex Approved as Part of Conditioning Regimen for HSCT in AML, MDS Patients
The Food and Drug Administration (FDA) has approved Grafapex ™ (treosulfan) for injection with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT) in ...
The American Journal of Managed Care3d
Treosulfan Regimen Approved for Allo-HSCT Conditioning in AML/MDS
The FDA approved treosulfan in combination with fludarabine as preparation for allogeneic hematopoietic stem cell ...